Adaptimmune Therapeutics plc (ADAP): Price and Financial Metrics
Adaptimmune Therapeutics plc (ADAP)
Today's Latest Price: $2.81 USD
0.04 (-1.40%)
Updated Mar 30 3:46pm
Add ADAP to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
ADAP Stock Summary
- With a price/sales ratio of 357.78, Adaptimmune Therapeutics PLC has a higher such ratio than 99.23% of stocks in our set.
- Revenue growth over the past 12 months for Adaptimmune Therapeutics PLC comes in at -98.11%, a number that bests merely 0.48% of the US stocks we're tracking.
- The volatility of Adaptimmune Therapeutics PLC's share price is greater than that of 96.21% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to ADAP, based on their financial statements, market capitalization, and price volatility, are GERN, CRNX, FIXX, INO, and SNDX.
- ADAP's SEC filings can be seen here. And to visit Adaptimmune Therapeutics PLC's official web site, go to www.adaptimmune.com.
ADAP Daily Price Range
ADAP 52-Week Price Range
ADAP Stock Price Chart More Charts
ADAP Price/Volume Stats
| Current price | $2.81 | 52-week high | $6.00 |
| Prev. close | $2.85 | 52-week low | $0.71 |
| Day low | $2.76 | Volume | 170,766 |
| Day high | $2.92 | Avg. volume | 2,051,142 |
| 50-day MA | $3.55 | Dividend yield | N/A |
| 200-day MA | $2.31 | Market Cap | 365.51M |
Adaptimmune Therapeutics plc (ADAP) Company Bio
Adaptimmune Therapeutics plc is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. The company was founded in 2014 and is based in Abingdon, the United Kingdom.
Top Stories View All
An Update on CannTrust (CTST) as it Awaits Crucial News from Health Cananda
2 Companies That are Bucking the Trend in the Stock Market
Top 4 Home Improvement Stocks with Stimulus Checks on the Way
Rip Your Face Off Rally!
Best & Worst Performing Stock Industries for March 27, 2020
View All Top Stories
Loading social stream, please wait...